Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy

Journal of Gene Medicine

Volumn 7, Issue 6, 2005, Pages 686-695

  Bonehill, Aude ^a   Heirman, Carlo ^a   Thielemans, Kris ^a  

^a FACULTY OF MEDICINE AND PHARMACY   (Belgium)

Author keywords

Cancer immunotherapy; CD4+ T helper cell; CD8+ CTL; HLA class II targeting

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; PROTEIN E7; TUMOR ANTIGEN; VIRUS VECTOR;

AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE INDUCTION; GENE TARGETING; GENE TRANSFER; HELPER CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; TH1 CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 21044457258     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.713     Document Type: Review

References (109)

1. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13: 545-586.
2. Noguchi Y, Richards EC, Chen YT, et al. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A 1995; 92: 2219-2223.
3. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 242-2249.
4. Mandelboim O, Vadai E, Fridkin M, et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995; 1: 1179-1183.
5. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-1302.
6. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
7. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
8. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219-230.
9. Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit Rev Immunol 1998; 18: 275-303.
10. Old LJ. Immunotherapy for cancer. Sci Am 1996; 275: 136-143.
11. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000; 21: 403-410.
12. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
13. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480.
14. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483.
15. Creusot RJ, Mitchison NA. How DCs control cross-regulation between lymphocytes. Trends Immunol 2004; 25: 126-131.
16. Kiener PA, Moran-Davis P, Rankin BM, et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995; 155: 4917-4925.
17. Koch F, Stanzl U, Jennewein P, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996; 184: 741-746.
18. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
19. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
20. Marzo AL, Kinnear BF, Lake RA, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 6047-6055.
21. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002; 297: 2060-2063.
22. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852-856.
23. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300: 337-339.
24. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300: 339-342.
25. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
26. Levitsky HI, Lazenby A, Hayashi RJ, et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994; 179: 1215-1224.
27. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
28. Mumberg D, Monach PA, Wanderling S, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 1999; 96: 8633-8638.
29. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-686.
30. Romano G, Michell P, Pacilio C, et al. Latest developments in gene transfer technology: achievement, perspectives, and controversies over therapeutic applications. Stem Cells 2000; 18: 19-39.
31. Van Tendeloo VF, Van Broeckhoven C, Berneman ZN. Gene therapy: principles and applications to hematopoietic cells. Leukemia 2001; 15: 523-544.
32. Breckpot K, Heirman C, Neyns B, et al. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004; in press.
33. Gromme M, Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 2002; 39: 181-202.
34. Van Kaer L. Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 2002; 60: 1-9.
35. Pieters J. MHC class II-restricted antigen processing and presentation. Adv Immunol 2000; 75: 159-208.
36. Wubbolts R, Neefjes J. Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors. Immunol Rev 1999; 172: 189-208.
37. Busch R, Doebele RC, Patil NS, et al. Accessory molecules for MHC class II peptide loading. Curr Opin Immunol 2000; 12: 99-106.
38. Cresswell P. Invariant chain structure and MHC class II function. Cell 1996; 84: 505-507.
39. Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends Immunol 2003; 24: 264-268.
40. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990; 63: 707-716.
41. Pieters J, Bakke O, Dobberstein B. The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. J Cell Sci 1993; 106: 831-846.
42. van Bergen J, Schoenberger SP, Verreck F, et al. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci U S A 1997; 94: 7499-7502.
43. Malcherek G, Wirblich C, Willcox N, et al. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur J Immunol 1998; 28: 1524-1533.
44. Fujii S, Senju S, Chen YZ, et al. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol 1998; 59: 607-614.
45. Carstens C, Newman DK, Bohlen H, et al. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation. Int Immunol 2000; 12: 1561-1568.
46. van Bergen J, Camps M, Offringa R, et al. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II- associated invariant chain peptide. Cancer Res 2000; 60: 6427-6433.
47. van Tienhoven EA, ten Brink CT, van Bergen J, et al. Induction of antigen specific CD4+ T cell responses by invariant chain based DNA vaccines. Vaccine 2001; 19: 1515-1519.
48. Fujii S, Uemura Y, Iwai LK, et al. Establishment of an expression cloning system for CD4+ T cell epitopes. Biochem Biophys Res Commun 2001; 284: 1140-1147.
49. Bischof F, Wienhold W, Wirblich C, et al. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes. Proc Natl Acad Sci U S A 2001; 98: 12 168-12 173.
50. Nagata T, Higashi T, Aoshi T, et al. Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization. Vaccine 2001; 20: 105-114.
51. Toda M, Kasai M, Hosokawa H, et al. DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen-specific IgE response. Eur J Immunol 2002; 32: 1631-1639.
52. Nagata T, Aoshi T, Suzuki M, et al. Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class II-associated invariant chain peptide of the invariant chain. Infect Immunol 2002; 70: 2676-2680.
53. Bonehill A, Heirman C, Tuyaerts S, et al. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res 2003; 63: 5587-5594.
54. Gregers TF, Fleckenstein B, Vartdal F, et al. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. Int Immunol 2003; 15: 1291-1299.
55. Nakano N, Rooke R, Benoist C, et al. Positive selection of T cells induced by viral delivery of neopeptides to the thymus. Science 1997; 275: 678-683.
56. Sponaas A, Carstens C, Koch N. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells. Gene Ther 1999; 6: 1826-1834.
57. Ignatowicz L, Winslow G, Bill J, et al. Cell surface expression of class II MHC proteins bound by a single peptide. J Immunol 1995; 154: 3852-3862.
58. Fremont DH, Hendrickson WA, Marrack P, et al. Structures of an MHC class II molecule with covalently bound single peptides. Science 1996; 272: 1001-1004.
59. Kozono H, White J, Clements J, et al. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 1994; 369: 151-154.
60. Crawford F, Kozono H, White J, et al. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 1998; 8: 675-682.
61. Kotzin BL, Falta MT, Crawford F, et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000; 97: 291-296.
62. Meyer AL, Trollmo C, Crawford F, et al. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci U S A 2000; 97: 11 433-11 438.
63. Cunliffe SL, Wyer JR, Sutton JK, et al. Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+ T cells in peripheral blood mononuclear cells. Eur J Immunol 2002; 32: 3366-3375.
64. Kirchhausen T. Adaptors for clathrin-mediated traffic. Annu Rev Cell Dev Biol 1999; 15: 705-732.
65. Kirchhausen T. Clathrin. Annu Rev Biochem 2000; 69: 699-727.
66. Robinson MS, Bonifacino JS. Adaptor-related proteins. Curr Opin Cell Biol 2001; 13: 444-453.
67. Kongsvik TL, Honing S, Bakke O, et al. Mechanism of interaction between leucine-based sorting signals from the invariant chain and clathrin-associated adaptor protein complexes AP1 and AP2. J Biol Chem 2002; 277: 16 484-16 488.
68. Williams MA, Fukuda M. Accumulation of membrane glycoproteins in lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail. J Cell Biol 1990; 111: 955-966.
69. Obermuller S, Kiecke C, von Figura K, et al. The tyrosine motifs of Lamp 1 and LAP determine their direct and indirect targetting to lysosomes. J Cell Sci 2002; 115: 185-194.
70. Sanderson S, Frauwirth K, Shastri N. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci U S A 1995; 92: 7217-7221.
71. Rohrer J, Schweizer A, Russell D, et al. The targeting of Lamp1 to lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to the membrane. J Cell Biol 1996; 132: 565-576.
72. Wang RF, Wang X, Atwood AC, et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999; 284: 1351-1354.
73. De Marco F, Hallez S, Brulet JM, et al. DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res 2003; 23: 1449-1454.
74. Chaux P, Vantomme V, Stroobant V, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 1999; 189: 767-778.
75. Schultz ES, Lethe B, Cambiaso CL, et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000; 60: 6272-6275.
76. Zhang Y, Chaux P, Stroobant V, et al. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 2003; 171: 219-225.
77. Breckpot K, Dullaers M, Bonehill A, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003; 5: 654-667.
78. Van Meirvenne S, Straetman L, Heirman C, et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9: 787-797.
79. Bonehill A, Heirman C, Tuyaerts S, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172: 6649-6657.
80. Thomson SA, Burrows SR, Misko IS, et al. Targeting a polyepitope protein incorporating multiple class II- restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol 1998; 72: 2246-2252.
81. Diebold SS, Cotten M, Koch N, et al. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 2001; 8: 487-493.
82. Lin X, Dashti A, Schinazi RF, et al. Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. FASEB J 1993; 7: 1070-1080.
83. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995; 92: 11 671-11 675.
84. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
85. Ji H, Chang EY, Lin KY, et al. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998; 78: 41-45.
86. Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999; 10: 2727-2740.
87. Kim TW, Hung CF, Boyd D, et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003; 171: 2970-2976.
88. Kim TW, Hung CF, Zheng M, et al. A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. J Biomed Sci 2004; 11: 493-499.
89. Cheng WF, Hung CF, Chai CY, et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 2001; 166: 6218-6226.
90. Lundstrom K. Alphavirus vectors as tools in cancer gene therapy. Technol Cancer Res Treat 2002; 1: 83-88.
91. Yamanaka R. Alphavirus vectors for cancer gene therapy (review). Int J Oncol 2004; 24: 919-923.
92. Bonini C, Lee SP, Riddell SR, et al. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 2001; 166: 5250-5257.
93. Rowell JF, Ruff AL, Guarnieri FG, et al. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J Immunol 1995; 155: 1818-1828.
94. Ruff AL, Guarnieri FG, Staveley-O'Carroll K, et al. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem 1997; 272: 8671-8678.
95. Wu JM, Wu B, Miagkov A, et al. Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy. Cell Immunol 2001; 208: 137-147.
96. Raviprakash K, Marques E, Ewing D, et al. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 2001; 290: 74-82.
97. Lu Y, Raviprakash K, Leao IC, et al. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 2003; 21: 2178-2189.
98. Marques ET, Jr., Chikhlikar P, de Arruda LB, et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 2003; 278: 37 926-37 936.
99. de Arruda LB, Chikhlikar PR, August JT, et al. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004; 112: 126-133.
100. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16: 364-369.
101. Su Z, Vieweg J, Weizer AZ, et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002; 62: 5041-5048.
102. Parra-López CA, Lindner R, Vidavsky I, et al. Presentation on class II MHC molecules of endogenous lysozyme targeted to the endocytic pathway. J Immunol 1997; 158: 2670-2679.
103. Jing SQ, Spencer T, Miller K, et al. Role of the human transferrin receptor cytoplasmic domain in endocytosis: localization of a specific signal sequence for internalization. J Cell Biol 1990; 110: 283-294.
104. Girones N, Alverez E, Seth A, et al. Mutational analysis of the cytoplasmic tail of the human transferrin receptor. Identification of a sub-domain that is required for rapid endocytosis. J Biol Chem 1991; 266: 19 006-19 012.
105. Fernandes DM, Vidard L, Rock KL. Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments. Eur J Immunol 2000; 30: 2333-2343.
106. You Z, Huang XF, Hester J, et al. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J Immunol 2000; 165: 4581-4591.
107. You Z, Huang X, Hester J, et al. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001; 61: 3704-3711.
108. You Z, Hester J, Rollins L, et al. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 2001; 61: 197-205.
109. Wang S, Bartido S, Yang G, et al. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol 1999; 163: 5820-5826.